Current Cancer Trials

Participate in One of These Clinical Trials

National Cancer Institute Trials:  

With a grant from the National Cancer Institute (NCI), more than 30 established, recognized clinical oncology programs have joined together to form the Northwest Community Oncology Research Program (NW NCORP).

MultiCare Health System is amongst a network of hospitals, clinics, physicians, and researchers working together to provide cancer education and access to new and unique cancer clinical trials to the men, women, and children in communities across Washington, Utah and Alaska.

Visit NW NCORP website for NCI Clinical Trials available at MultiCare

Other Cancer Clinical Trials offered by MultiCare Health System

Phase I


A Phase 1/2, Open-label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10296 in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Protocol Summary


An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination With Radiotherapy in Patients With Advanced Solid Tumors

Protocol Summary

INCB 57643-101

A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Protocol Summary



Phase II Trial of Metronomic Eribulin (Halaven) In Pretreated Metastatic Breast Cancer (MBC)

Protocol Summary


-None at this time-



A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Protocol Summary

Head and Neck


A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Topically-applied AG013 for the Attenuation of Oral Mucositis in Subjects With Cancers of the Head and Neck Receiving Concomitant Chemoradiation Therapy

Protocol Summary


PCYC-1134 M

informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia

Protocol Summary


DSP-DE-MS 14-009

A Study to Determine the Concordance of Key Actionable Genomic Alterations as Assessed in Tumor Tissue and Plasma From Patients With Non Small Cell Lung Carcinoma (NSCLC)

Protocol Summary


A Phase III, Open-label, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-based Chemotherapy in PD-L1-Selected Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer

Protocol Summary

SCCA 7755

A Phase II study of weekly Abraxane (nab-paclitaxel) for patients with advanced NSCLC with EGFR mutations following front-line therapy with EGFR tyrosine kinase inhibitors

Protocol Summary


Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) Versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial)

Protocol Summary


-None at this time-



Direct Oral Anticoagulents (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer:  A Randomized Effectiveness Trial (CANVAS Trial)

Protocol Summary

Precision Med 6504

Collection of Blood, Urine and Tissue Samples from Patients with Solid Malignant Tumors

No protocol summary available.  Contact Tristin Baxter for more information:  253-403-1269



TRITON3:  A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration/resistant Prostate Cancer Associated with Homologous Recombination Deficiency

Protocol Summary

For more information contact Michelle Maxin-Wells at 253-403-7193 or [email protected]